{"id":976419,"date":"2026-06-29T07:30:07","date_gmt":"2026-06-29T11:30:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\/"},"modified":"2026-06-29T07:30:07","modified_gmt":"2026-06-29T11:30:07","slug":"sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\/","title":{"rendered":"Sagimet Biosciences Joins the Russell 2000\u00ae and Russell 3000\u00ae Indexes"},"content":{"rendered":"
\n

SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company has been added to the broad-market Russell 3000\u00ae Index and small-cap Russell 2000\u00ae Index, effective at the open of U.S. equity markets today, as part of the 2026 Russell Indexes reconstitution.<\/p>\n

The June reconstitution of the Russell US indexes captures up to the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000\u00ae Index, which remains in place for half a year beginning in 2026, means automatic inclusion in the large-cap Russell 1000\u00ae Index or small-cap Russell 2000\u00ae Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.<\/p>\n

\u201cWe believe inclusion in the Russell indexes reflects the meaningful progress Sagimet has made over the last year, as we plan to initiate our U.S. Phase 3 clinical trial of denifanstat in moderate to severe acne, including adolescent patients aged 12 years and older, in the second half of this year. If approved, denifanstat would be the first innovative oral treatment for acne vulgaris in patients aged 12 years and older in more than forty years,\u201d said David Happel, Chief Executive Officer of Sagimet. \u201cWith the capital in place to fund our programs through 2028, including data readout of our planned denifanstat Phase 3 clinical trial in acne, we look forward to the broader visibility that inclusion in the Russell indexes brings.\u201d<\/p>\n

For further information on Russell index methodology and reconstitution, please visit FTSE Russell at www.lseg.com\/en\/ftse-russell<\/a>.<\/p>\n

\n About\u00a0Sagimet Biosciences<\/strong>\n <\/p>\n

Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, and a key pathway implicated in multiple diseases, such as acne, MASH\u202fand certain FASN-dependent tumor types. For additional information about Sagimet, please visit\u00a0www.sagimet.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding the expected timing of the presentation of data from ongoing clinical trials, Sagimet\u2019s clinical development plans and related timelines and anticipated development milestones, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause Sagimet\u2019s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, these statements can be identified by terms such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201caim,\u201d \u201cseek,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201ccontemplate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cforecast,\u201d \u201cpotential\u201d or \u201ccontinue\u201d or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. Sagimet has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Sagimet believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Sagimet\u2019s control, including, among others: the clinical development and therapeutic potential of denifanstat, TVB-3567 or any other drug candidates or combination therapies developed by Sagimet; Sagimet\u2019s ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines; Sagimet\u2019s relationship with\u00a0Ascletis, and the success of its development efforts for denifanstat; the accuracy of Sagimet\u2019s estimates regarding its capital requirements and Sagimet\u2019s ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the \u201cRisk Factors\u201d section of Sagimet\u2019s most recent filings with the Securities and Exchange Commission and available at\u00a0www.sec.gov<\/a>. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in these forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, Sagimet operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Sagimet may face. Except as required by applicable law, Sagimet does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.<\/p>\n

\n Investor Contact:<\/strong>
\n
Joyce Allaire\u00a0
LifeSci Advisors\u00a0
JAllaire@LifeSciAdvisors.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company has been added to the broad-market Russell 3000\u00ae Index and small-cap Russell 2000\u00ae Index, effective at the open of U.S. equity markets today, as part of the 2026 Russell Indexes reconstitution. The June reconstitution of the Russell US indexes captures up to the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000\u00ae Index, which remains in place for half a year beginning in 2026, means automatic inclusion in the large-cap Russell 1000\u00ae Index or small-cap Russell 2000\u00ae Index … <\/p>\n

Continue reading “Sagimet Biosciences Joins the Russell 2000\u00ae and Russell 3000\u00ae Indexes”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-976419","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSagimet Biosciences Joins the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sagimet Biosciences Joins the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company has been added to the broad-market Russell 3000\u00ae Index and small-cap Russell 2000\u00ae Index, effective at the open of U.S. equity markets today, as part of the 2026 Russell Indexes reconstitution. The June reconstitution of the Russell US indexes captures up to the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000\u00ae Index, which remains in place for half a year beginning in 2026, means automatic inclusion in the large-cap Russell 1000\u00ae Index or small-cap Russell 2000\u00ae Index … Continue reading "Sagimet Biosciences Joins the Russell 2000\u00ae and Russell 3000\u00ae Indexes"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-29T11:30:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzI3OCM3NjgwMjA2IzIyMDg2NDg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sagimet Biosciences Joins the Russell 2000\u00ae and Russell 3000\u00ae Indexes\",\"datePublished\":\"2026-06-29T11:30:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\\\/\"},\"wordCount\":837,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MzI3OCM3NjgwMjA2IzIyMDg2NDg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\\\/\",\"name\":\"Sagimet Biosciences Joins the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MzI3OCM3NjgwMjA2IzIyMDg2NDg=\",\"datePublished\":\"2026-06-29T11:30:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MzI3OCM3NjgwMjA2IzIyMDg2NDg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MzI3OCM3NjgwMjA2IzIyMDg2NDg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sagimet Biosciences Joins the Russell 2000\u00ae and Russell 3000\u00ae Indexes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sagimet Biosciences Joins the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\/","og_locale":"en_US","og_type":"article","og_title":"Sagimet Biosciences Joins the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk","og_description":"SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company has been added to the broad-market Russell 3000\u00ae Index and small-cap Russell 2000\u00ae Index, effective at the open of U.S. equity markets today, as part of the 2026 Russell Indexes reconstitution. The June reconstitution of the Russell US indexes captures up to the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000\u00ae Index, which remains in place for half a year beginning in 2026, means automatic inclusion in the large-cap Russell 1000\u00ae Index or small-cap Russell 2000\u00ae Index … Continue reading \"Sagimet Biosciences Joins the Russell 2000\u00ae and Russell 3000\u00ae Indexes\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-29T11:30:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzI3OCM3NjgwMjA2IzIyMDg2NDg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sagimet Biosciences Joins the Russell 2000\u00ae and Russell 3000\u00ae Indexes","datePublished":"2026-06-29T11:30:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\/"},"wordCount":837,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzI3OCM3NjgwMjA2IzIyMDg2NDg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\/","name":"Sagimet Biosciences Joins the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzI3OCM3NjgwMjA2IzIyMDg2NDg=","datePublished":"2026-06-29T11:30:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzI3OCM3NjgwMjA2IzIyMDg2NDg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzI3OCM3NjgwMjA2IzIyMDg2NDg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sagimet Biosciences Joins the Russell 2000\u00ae and Russell 3000\u00ae Indexes"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/976419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=976419"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/976419\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=976419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=976419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=976419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}